Conditions: Atopic Dermatitis Healthy Volunteers
Keywords: atopic dermatitis skin diseases healthy volunteer
Allocation: RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 78
Healthy volunteers: yes

Brief summary:
This study is a single dose escalation study of tezepelumab (AMG 157) in healthy adults (Part A) and adults with moderate to severe atopic dermatitis (Part B). The purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of tezepelumab.

Detailed description:

Arms:
arm 1: Participants will receive a single dose of tezepelumab administered subcutaneously or intravenously. The starting dose will be 2.1 mg tezepelumab. arm 2: Participants will receive matching placebo administered subcutaneously or intravenously.

Interventions: intervention 1: Tezepelumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered by subcutaneous or intravenous injection intervention 2: Matching placebo administered by subcutaneous or intravenous injection.

Protocol document: